- Following an agreement with the South Africa Government for the supply of 6 million vaccine doses to contain the ongoing foot-and-mouth disease outbreak, the company presented Bioaftogen®, its world-class FMD vaccine, together with best vaccination practices, to experts, livestock producers and key industry stakeholders.
- With an available portfolio comprising more than 10 antigenic combinations, Bioaftogen®, produced and exported from Argentina, is positioned as a world-class solution in the fight against foot-and-mouth disease.
Biogénesis Bagó officially presented Bioaftogen®, its high-potency vaccine designed to strengthen foot-and-mouth disease prevention and contribute to the development of sustainable livestock production on a global scale, in South Africa. The event brought together livestock producers, veterinarians, industry leaders and key stakeholders in the animal health sector from South Africa and other African countries. The presentation was led by Dr. Rodolfo Bellinzoni, Director of Innovation and Industrial Operations; Sebastián Perretta, Executive Business Director; Daniel Helou, Regional Director of MENA, and Facundo Romero, Strategic Marketing Manager.
The company, which currently has the capacity to produce 350 million doses per year, was recently selected to be part of South Africa’s national vaccination program and completed the export of the first one million doses to the country last month. Additional shipments are scheduled throughout March as part of the local animal health emergency, which is causing significant losses for producers and having a strong impact on the local economy and exports.
With more than 3.4 billion doses administered over the past 30 years and more than 35 licenses in 25 countries, Bioaftogen® was the first high-potency foot-and-mouth disease vaccine (>32 PD50) to obtain prequalification from the European Commission for the Control of Foot-and-Mouth Disease (EuFMD). It is the only vaccine capable of combining all seven virus serotypes, designed to meet the specific epidemiological needs of each market or region.
The vaccine stands out for its high potency, excellent safety profile and long-lasting immunity, together with a 24-month shelf life. In addition, its DIVA technology enables differentiation between vaccinated and naturally infected animals, a key feature for its use in disease control and eradication programs.
of foot-and-mouth disease.– Today, it protects the health of more than 1.1 billion animals and “Bioaftogen® is a world class vaccine developed to address the most demanding challenges is exported to over 20 countries. At Biogénesis Bagó, we combine innovation, quality and industrial capacity, while also providing technical expertise and experience to support the implementation of effective and efficient animal health strategies on a global scale” said Dr. Rodolfo Bellinzoni, Director of Innovation and Industrial Operations at Biogénesis Bagó.
Backed by decades of innovation and global-scale industrial capacity, Biogénesis Bagó will continue to support South African authorities and farmers through additional vaccine deliveries, specialized technical advisory services and strategic recommendations to help control the local foot-and-mouth disease outbreak.
